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Discussion
Dr J. William Gaynor (Philadelphia, Pa). I would like to
congratulate the authors on a very nice study and an excellent
presentation. It is always nice to discuss a paper that agrees with
your own beliefs.
We switched to del Nido at the Children’s Hospital in
Philadelphia several years ago, and we currently use it for all of
our patients from neonates to the young adults. We do not have
elderly patients very frequently at CHOP, but we do go into the
30- and 40-year-olds.
Our clinical experience mimics this completely. We usually use
a single dose. We see very little return of spontaneous activity, and
we have been very happy with the postoperative function.
That being said, when we retrospectively compared our early
outcomes, inotropic use, and everything to our previous crystalloid
cardioplegia, we could show no differences. So our anecdotal
experience is that we like it, it seems to facilitate the operation
by only having to give one dose, we do see less spontaneous
activity, but we cannot show a clinical difference.
Now, when you go to, as you mentioned in your future
directions, you move to elderly patients, you are going to be
dealing with myocardium that is ischemic or perhaps has beenrdiovascular Surgery c Volume 146, Number 4 947
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situation. So how do we move forward from this isolated heart
model of essentially elderly but normal myocardium to a clinical
trial where we can actually show a difference? Because I am afraid
it would take somany patients as to become not feasible to perform
that study. But that being said, we use del Nido, we are very happy
with it, and we do think it is a better myocardial protective strategy.
Thank you very much. I enjoyed your paper.
Mr Govindapillai. Thank you, Dr Gaynor. To try and answer
your question, I think that what needs to happen is we need to
look at a whole animal model first. There are some concerns in
terms of single dosing with del Nido with adult patients where pro-
cedures can be pretty long and so sometimes re-dosing can occur
over longer intervals than with our standard cardioplegia where948 The Journal of Thoracic and Cardiovascular Surgit is given in shorter intervals. But I think certainly the next step
would be to look at a whole animal model and see where the in-
flammatory system plays a role as well and that would be, to me,
the next logical step before you can move on to some sort of a clin-
ical trial, and hopefully we can see some differences there as well.
Dr Gaynor. We occasionally use multidose if we have a
particularly long cross-clamp or in the rare case where we do see
a return of activity, and it works very well if you give an additional
dose. But again, I think I agree with the findings, I think it is an
excellent protective strategy, I think it probably is applicable to a
wider range of patients, but I do think it is going to be very hard
to prove that in a clinical setting.
Thank you very much.
Mr Govindapillai. Thank you.ery c October 2013
